Antares Pharma to Report Second Quarter 2020 Operating and Financial Results
July 30 2020 - 7:00AM
Antares Pharma, Inc. (NASDAQ: ATRS), a pharmaceutical technology
company, today announced it will release its second quarter 2020
financial results and recent operating progress before the market
opens on Thursday, August 6, 2020. Management will host a
webcast and conference call at 8:30 a.m. ET (Eastern Time) on
August 6, 2020 to discuss the results.
Interested parties may participate in the
conference call by dialing 1-800-353-6461 or 1-334-323-0501 and
entering access code 5888699. We encourage interested parties
to dial into the conference call at least 10 minutes prior to the
scheduled start time. A replay of the conference call will be
available from 11:30 a.m. ET on Thursday, August 6, 2020 through
11:30 a.m. ET on Saturday, September 5, 2020 by dialing
1-888-203-1112 or 1-719-457-0820 and entering the access code
5888699. An archive of the slide presentation will also be
available under the “For Investors” section of the Antares Website
at www.antarespharma.com.
About Antares Pharma
Antares Pharma, Inc. is a pharmaceutical
technology company focused primarily on the development and
commercialization of self-administered injectable pharmaceutical
products using advanced drug delivery auto injector
technology. The Company has a portfolio of proprietary and
partnered commercial products with several product candidates in
various stages of development, as well as significant strategic
alliances with industry leading pharmaceutical companies including
Teva Pharmaceutical Industries, Ltd. (Teva), AMAG Pharmaceuticals,
Inc. (AMAG), Pfizer Inc. (Pfizer) and Idorsia Pharmaceuticals Ltd.
(Idorsia). Antares Pharma’s proprietary products include
XYOSTED® (testosterone enanthate) injection, OTREXUP®
(methotrexate) injection for subcutaneous use and Sumatriptan
Injection USP, which is distributed by Teva.
SAFE HARBOR STATEMENT UNDER THE PRIVATE
SECURITIES LITIGATION REFORM ACT OF 1995
This press release contains
forward-looking statements within the meaning of the safe harbor
provisions of the Private Securities Litigation Reform Act of
1995. Forward-looking statements are subject to certain risks
and uncertainties that can cause actual results to differ
materially from those described. Factors that may cause such
differences include, but are not limited to: the uncertainty
regarding the duration, scope and severity of the COVID-19 pandemic
and the mitigation measures and other restrictions implemented in
response to the same and the impact on demand for our products, new
patients and prescriptions, future revenue, product supply, and our
overall business, operating results and financial condition; market
acceptance, adequate reimbursement coverage and commercial success
of XYOSTED® and future revenue from the same; successful
development including the timing and results of the clinical
bridging and Phase 3 clinical trial of the drug device combination
product for Selatogrel with Idorsia Pharmaceuticals and FDA and
global regulatory approvals and future revenue from the same;
market acceptance of Teva’s generic epinephrine auto-injector
product and future revenue from the same; our expectations
regarding whether the FDA will pursue withdrawal of approval for
AMAG Pharmaceuticals Inc.’s Makena® subcutaneous auto injector
following the recent FDA advisory committee meeting and future
prescriptions, market acceptance and revenue from Makena®
subcutaneous auto injector; Teva’s ability to successfully
commercialize VIBEX® Sumatriptan Injection USP and the amount of
revenue from the same; continued growth of prescriptions and sales
of OTREXUP®; the timing and results of the Company’s or its
partners’ research projects or clinical trials of product
candidates in development; actions by the FDA or other
regulatory agencies with respect to the Company’s products or
product candidates of its partners; continued growth in product,
development, licensing and royalty revenue; the Company’s ability
to meet loan extension and interest only payment milestones and the
ability to repay the debt obligation to Hercules Capital; the
Company’s ability to obtain financial and other resources for its
research, development, clinical, and commercial activities and
other statements regarding matters that are not historical facts,
and involve predictions. These statements involve known and unknown
risks, uncertainties and other factors that may cause actual
results, performance, achievements or prospects to be materially
different from any future results, performance, achievements or
prospects expressed in or implied by such forward-looking
statements. In some cases you can identify forward-looking
statements by terminology such as ''may'', ''will'', ''should'',
''would'', ''expect'', ''intend'', ''plan'', ''anticipate'',
''believe'', ''estimate'', ''predict'', ''potential'', ''seem'',
''seek'', ''future'', ''continue'', or ''appear'' or the negative
of these terms or similar expressions, although not all
forward-looking statements contain these identifying words.
Additional information concerning these and other factors that may
cause actual results to differ materially from those anticipated in
the forward-looking statements is contained in the "Risk Factors"
section of the Company's Annual Report on Form 10-K, and in the
Company's other periodic reports and filings with the Securities
and Exchange Commission. The Company cautions investors not
to place undue reliance on the forward-looking statements contained
in this press release. All forward-looking statements are based on
information currently available to the Company on the date hereof,
and the Company undertakes no obligation to revise or update these
forward-looking statements to reflect events or circumstances after
the date of this press release, except as required by
law.
Contacts:Jack HowarthVice President, Corporate
Affairs609-359-3016jhowarth@antarespharma.com
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Jul 2023 to Jul 2024